NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox
NanoViricides (NYSE-A:NNVC) is preparing a Phase II clinical trial application for its lead antiviral candidate NV-387 to treat Mpox infections…
Echtzeit-Aktienkurs Nanoviricides Inc.
Bid:
Ask:
Nachrichten zur Nanoviricides Inc. Aktie
NanoViricides progresses antiviral portfolio as measles and MPox threats rise
NanoViricides Inc (NYSE American: NNVC) said on Wednesday it is moving forward with trials of its antiviral drug NV-387 to…
NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC
NanoViricides (NYSE-A:NNVC) said on Thursday it has received ethics committee approval in the Democratic Republic of Congo to move forward…
NanoViricides advances measles drug development amid rising US cases
NanoViricides (NYSE-A:NNVC) said it is moving forward with the development of a drug to treat measles, as US health officials…
NanoViricides evaluating antiviral drug NV-387 for measles treatment
NanoViricides (NYSE-A:NNVC) has begun evaluating its clinical-stage antiviral NV-387 for the treatment of measles, a disease with no currently approved…
NanoViricides unaffected by US tariff turmoil, says CFO
NanoViricides (NYSE-A:NNVC) chief financial officer Meeta Vyas talked with Proactive about the company’s progress developing broad-spectrum antiviral...…
NanoViricides unimpacted by tariffs; sees boost by changes at government agencies
…
NanoViricides highlights broad-spectrum antiviral strategy and progress with lead drug candidate
…
NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative
The US Department of Agriculture (USDA) will invest up to $100 million to combat highly pathogenic avian influenza (HPAI), funding…
NanoViricides says business unaffected by US tariffs, highlights antiviral pipeline
NanoViricides (NYSE-A:NNVC) said on Tuesday that its business remains unaffected by US government tariffs, retaliatory trade policies, or federal spending...…
Mpox – a possible US$100mln+ opportunity
Nanoviricides (NV), a US company, targets the unmet medical need for an effective, broad-spectrum acute antiviral therapy with NV-387. NV…
NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials
NanoViricides (NYSE-A:NNVC) is positioning itself for a pivotal year in 2025, with plans to advance its lead antiviral candidate, NV-387,…
NanoViricides announces readiness to combat bird flu with antiviral drug NV-387
NanoViricides (NYSE-A:NNVC) stated today that it is prepared to address the escalating threat of bird flu with its broad-spectrum antiviral…
NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387
With its broad-spectrum antiviral drug NV-387, NanoViricides (NYSE-A:NNVC) sees a future where patients with a range of viral diseases can access…
NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts
Bird flu is likely widespread among birds in Massachusetts, State health and environmental officials said this week on Wednesday, as…
NanoViricides advances antiviral drug with Phase II Clinical trial to Combat MPox
…
NanoViricides taps clinical research organization for Phase II trial of NV-387
NanoViricides (NYSE-A:NNVC) said on Monday it had engaged a clinical research organization to conduct a Phase II trial for its…
NanoViricides CEO discusses NV-387’s broad spectrum promise
NanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan joined Proactive to highlight the company’s lead drug candidate NV-387, which is targeting multiple…
NanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threats
NanoViricides (NYSE-A:NNVC) has highlighted the growing need for innovative antiviral solutions amid rising concerns over multiple viral threats, including...…
NanoViricides CEO discusses groundbreaking broad-spectrum antiviral treatment
…
NanoViricides sees NV-387 as a key defense against bird flu pandemic
NanoViricides (NYSE-A:NNVC) said it believes that its broad-spectrum antiviral candidate, NV-387, could be a critical tool in combating a potential…
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America
The rise of unexplained human cases of bird flu in North America means there is an urgent need for effective…
NanoViricides pushes NV-387 to Phase II trials
NanoViricides (NYSE-A:NNVC) reported progress on its lead antiviral drug NV-387 and revealed plans to advance Phase II clinical trials for…
NanoViricides prepares for Phase II trials for antiviral NV-387
NanoViricides (NYSE-A:NNVC) filed its annual report, announcing that its broad-spectrum antiviral NV-387 is progressing to Phase II clinical trials, with...…
NanoViricides expands antiviral drug pipeline with TheraCour Pharma agreement
NanoViricides (NYSE-A:NNVC) announced that it has signed a Memorandum of Understanding (MOU) with TheraCour Pharma, granting it the right of…
NanoViricides CEO talks lead drug asset’s potential as MPOX therapy
NanoViricides (NYSE-A:NNVC) CEO Anil Diwan joined Proactive to discuss the promise of its lead drug NV-387 as a broad-spectrum antiviral.…
NanoViricides exploring emergency protocol to evaluate NV-387 for MPOX
NanoViricides (NYSE-A:NNVC) announced that it is investigating the potential use of its lead drug candidate NV-387 to treat MPOX patients…
NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387
NanoViricides (NYSE-A:NNVC) is advancing its clinical program with plans for an innovative Phase II trial of its drug candidate NV-387,…
NanoViricides reports major progress in advancing broad-spectrum antiviral drug NV-387
NanoViricides (NYSE-A:NNVC) has highlighted significant progress made in advancing its lead drug candidate NV-387 during the 2024 fiscal year 2024,…
NanoViricides’ lead asset for broad spectrum efficacy wins praise in industry reports
NanoViricides (NYSE-A:NNVC) has announced the publication of two independent reports on the company by industry analysts which highlight the potential…
NanoViricides’ lead asset with broad spectrum efficacy represents paradigm shift: analysts
NanoViricides (NYSE-A:NNVC)’ broad spectrum drug candidate NV-387 could present “a new paradigm shift in viral therapy,” according to a new…
NanoViricides’ lead asset for broad spectrum efficacy represents paradigm shift: analysts
NanoViricides (NYSE-A:NNVC) has announced the publication of two independent reports on the company by industry analysts which highlight the potential…
NanoViricides spotlights lead drug candidates potential as COVID therapy
NanoViricides (NYSE-A:NNVC) has highlighted the strong safety and efficacy of its lead clinical drug candidate NV-387 against coronaviruses. Animal studies...…
NanoViricides discusses lead program and next steps
NanoViricides (NYSE-A:NNVC), a leader in broad-spectrum antiviral nanomedicines, is advancing its development program for NV-387. This single drug has shown...…
NanoViricides hails broad potential of lead antiviral drug as it prepares to begin first Phase II trial
NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, highlighted the efficacy of its lead drug, NV-387 against a range of...…
NanoViricides hails the potential of NV-387 in combatting bird flu virus H5N1
NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, believes its drug NV-387 could be crucial in fighting the bird flu…
NanoViricides says antiviral drug candidate shows promise in protecting lungs against Influenza A
NanoViricides (NYSE-A:NNVC) announced that its ultra-broad-spectrum antiviral drug candidate NV-387 demonstrated effectiveness in protecting lungs from...…
NanoViricides antiviral candidate may be first effective oral nanomedicine
NanoViricides (NYSE-A:NNVC) said its lead antiviral candidate, NV-387, was found to be highly active when taken orally, making potentially the first...…
NanoViricides says lead asset exhibits desirable blood concentration profile for infrequent dosing
NanoViricides (NYSE-A:NNVC) has unveiled additional positive data for its lead clinical-stage broad-spectrum antiviral agent NV-387, a desirable blood...…
NanoViricides CEO says lead asset NV-387 could be ‘holy grail’ of antiviral medicines
NanoViricides (NYSE-A:NNVC) is developing a first-in-class, broad-spectrum anti-viral agent NV-387 that it believes could revolutionize the treatment of...…
NanoViricides taps Aagami to seek out licensing and partnership opportunities
NanoViricides (NYSE-A:NNVC) announced that it has engaged Chicago-based life sciences consultancy firm Aagami for business development, specifically to seek...…
NanoViricides could generate ‘antiviral superdrug’ for multiple diseases, analysts believe
NanoViricides (NYSE-A:NNVC) has been awarded a ‘Buy’ rating and $6.50 price target by analysts at EF Hutton following the release…
Novel anti-viral could boost a US$3 bln market
New focus on viral respiratory infections especially highly transmissible RSV NanoViricides (NYSE-A:NNVC) (NV), a US company, owns a novel, multi-target,...…
NanoViricides reports strong antiviral activity of NV-387 against RSV
NanoViricides (NYSE-A:NNVC) has reported that its antiviral drug candidate NV-387 demonstrated significant efficacy against respiratory syncytial virus...…
NanoViricides shares gain as new data shows lead drug assets strong activity against RSV
NanoViricides (NYSE-A:NNVC) has released new data which shows the strength of the antiviral activity of its lead drug asset NV-387…
NanoViricides unveils new data showing lead drug asset’s strong activity against RSV
NanoViricides (NYSE-A:NNVC) has released new data which shows the strength of the antiviral activity of its lead drug asset NV-387…
NanoViricides CEO discusses NV-387’s broad-spectrum antiviral potential
NanoViricides (NYSE-A:NNVC) has released a slew of new data supporting the safety and ultra-broad antiviral activity of its investigational therapeutic...…
NanoViricides to showcase lead drug asset’s progress at EF Hutton Annual Global Conference
NanoViricides (NYSE-A:NNVC) announced that members of its leadership team will be attending the EF Hutton Annual Global Conference being held…
NanoViricides to showcase lead drug asset’s progress at global conference
NanoViricides (NYSE-A:NNVC) announced that members of its leadership team will be attending the EF Hutton Annual Global Conference being held…
NanoViricides says lead asset shows antiviral activity against Smallpox and Mpox
NanoViricides (NYSE-A:NNVC) told investors that the ultra-broad antiviral activity spectrum of its lead drug asset NV-387 includes activity against the...…